Cytokines to reduce platelet transfusions: Non-TPO cytokines

Transfusion Science

Volumn 18, Issue 1, 1997, Pages 121-128

  Hamblin, Terry ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; CYTOKINE RECEPTOR; INTERLEUKIN 11; INTERLEUKIN 3; INTERLEUKIN 6; INTERLEUKIN DERIVATIVE; LEUKEMIA INHIBITORY FACTOR; ONCOSTATIN M; SC 55494; STEM CELL FACTOR; SYNTHOKINE; THROMBOPOIETIN; UNCLASSIFIED DRUG;

ANEMIA; ARTHRALGIA; BLOOD COMPONENT THERAPY; BODY WEIGHT DISORDER; BONE MARROW SUPPRESSION; BONE PAIN; BREAST CANCER; CACHEXIA; CARDIOVASCULAR DISEASE; CELL MATURATION; CELL PROLIFERATION; CHEMICAL STRUCTURE; CLINICAL TRIAL; FATIGUE; FEVER; FLU LIKE SYNDROME; GENE MAPPING; HEADACHE; HUMAN; MEGAKARYOCYTE; MYALGIA; NONHUMAN; REVIEW; SKIN MANIFESTATION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; WEIGHT REDUCTION;

EID: 0347307501     PISSN: 09553886     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-3886(96)00088-4     Document Type: Article

References (53)

1. Ihle JN, Pepersack L, Rebar L: Regulation of T-cell differentiation: in vitro induction of 20 alfa hydroxysteroid dehydrogenase in splenic lymphocytes from athymic mice by a unique lymphokine. J Immunol 1981; 126:2184-2189.
2. Schrader JW: The panspecific hemopoietin of activated T lymphocytes (interleukin-3). Ann Rev of Immunol 1986; 4:205-230.
3. Le Beau MM, Epstein MD, O'Brien SJ, et al.: The interleukin-3 gene is located on the human chromosome 5 and is deleted in myeloid leukaemia with a deletion of 5q. Proc Nat Acad Sci, 1987, 84, 5913-5917.
4. Clark-Lewis I, Schrader JW: Molecular structure and biological activities of P-cell stimulating factor (interleukin-3), in Schrader JW, (ed.), Lymphokines, Vol. 15. Academic Press, San Diego, 1988, pp. 1-37.
5. Kitamura T, Sato N, Arai K, Miyajima A: Expression cloning of the human IL-3 receptor cDNA reveals a shared beta subunit for the human IL-3 and GM-CSF receptors. Cell 1991; 66:1165-1174.
6. Ihle JN: Biochemical and biological properties of intaleukin-3: a lymphokine mediating the differentiation of a lineage of cells that includes prothymocytes and mastlike cells, in Gillis S, Inman FP, (eds), Contempory topics in molecular immunology, Vol. 10. Plenum Press, New York, 1984, pp. 93-119.
7. Lord BI, Molineux G, Testa NG, Kelly M, Spooncer E, Dexter TM: The kinetic response of haemopoietic precursor cells, in vivo, to highly purified recombinant interleukin 3. Lymphokine Res 1986; 5:97-104.
8. Ganser A, Lindemann A, Seipelt G, et al.: Effects of recombinant interleukin-3 in patients with normal haematopoiesis and in patients with bone marrow failure. Blood 1990; 76:666-676.
9. D'Hondt V, Weynants P, Humblet, et al: Dose dependent interleukin-3 stimulation of thrombopiesis and neutropoiesis, in patients with small cell lung cancer before and following chemotherapy: a placebo controlled randomized study. J Clin Oncol 1993; 11:2063-2071.
10. Postmus PE, Gietema JA, Damsma O, et al.: Effects of recombinant interleukin-3 in patients with relapsed small lung cancer treated with chemotherapy: a dose finding study. J Clin Oncol 1992; 10:113-140.
11. Biesma B, Willemse PH, Mulder NH, et al.: Effects of interleukin-3 after chemotherapy for ovarian cancer. Blood 1992; 80:1141-1148.
12. Brugger W, Frisch J, Schulz G, Pressler K, Mertelsmann R, Kanz L: Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following standard-dose combination chemotherapy with etoposide, ifosfamide and cisplatin. J Clin Oncol 1992; 10:1452-1459.
13. Oshaughnessy JA, Venzon DJ, Gossard M, et al.: A phase I study of sequential versus concurrent interleukin-3 and granulocyte-macrophage colony-stimulating factor in advanced breast cancer patients treated with FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy. Blood 1995; 86:2913-2921.
14. Vadhan RS, Papadopoulos NE, Burgess MA, et al.: Effects of PlXY321, a granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein, on chemotherapy-induced multilineage myelosuppression in patients with sarcoma. J Clin Oncol 1994; 12:715-724.
15. Ghielmini M, Pettengell R, Coutinho LH, Testa N, Crowther D: The effects of the GM-CSF/IL-3 fusion protein PY321 on bone marrow and circulating haemopoietic cells of previously untreated patients with cancer. Br J Haematol 1996; 93:6-12.
16. Farese AM, Herodin F, Mckeam JP, Baum C, Burton E, Macvittie TJ: Acceleration of haematopoietic reconstitution with a synthetic cytokine (SC-55494) after radiation-induced bone marrow aplasia. Blood 1996; 87:581-591.
17. Billiau A: Interferon α2 as a promoter of growth and differentiation of B cells. Immunology Today 1987; 8:84-87.
18. Wong GC, Clark SC: Multiple actions of interleukin-6 within a cytokine network. Immunol Today 1988; 9:137-139.
19. Hirano T, Akira S, Taga T, Kishimoto T: Biological and clinical aspects of interleukin-6. Immunol Today 1990; 11:443-449.
20. Caracciolo D, Clar SC, Rovera G: Human interleukin-6 supports granulocytic differentiation of haematopoietic progenitor cells and acts synergistically with GM-CSF. Blood 1989; 73:666-670.
21. Suematsu S, Matsuda T, Aozasa K, et al.: IgG 1 plasmacytosis in interleukin-6 transgenic mice. Proc the Nat Acad of Sci of U.S.A., 1989, 75, pp. 47-51.
22. Klein B, Wijdenes J, Zhang XG, et al.: Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 1991; 78:1198-1204.
23. D'Hondt V, Humblet Y, Guillaume T, et al.: Therapeutic effects and toxicity of interleukin-6 in patients with ovarian cancer before and after chemotherapy: a multicentric, placebo-controlled, randomized phase 1b study. Blood 1995; 85:2347-2353.
24. Lazarus HM, Winton EF, Williams SF: Phase-I study of human interleukin-6 after autologous bone marrow transplantation in patients with poor prognosis breast cancer. Blood 1993; 82(1):173a.
25. Paul SR, Bennett F, Calvetti JA, et al.: Molecular cloning of a cDNA encoding interleukin-11, a stromal cell derived lymphopoietic and hematopoietic cytokine. Proc Nat Acad of Sci 1990; 87:7512-7516.
26. McKinley D, Wu Q, Yang-Feng T, Yang YC: Genomic sequence and chromosomal location of human interleukin-11 gene (IL-11). Genomics 1992; 13:814-819.
27. Yin T, Schendel P, Yu-Chung Y: Enhancement of in vitro and in vivo antigen specific antibody responses by interleukin-11. J Exp Med 1992; 175:211-216.
28. Teramura M, Kobayashi S, Hoshino S, Oshimi K, Mizoguchi H: Interleukin-11 enhances human megakaryocytopoiesis in vitro. Blood 1992; 79:327-331.
29. Kawashima I, Ohsumi J, Mita-Honjo K, et al.: Molecular cloning of cDNA encoding adipogenesis inhibitory factor and identity with interleukin-11. FEBS Letts 1991; 283:199-202.
30. Du XX, Neben T, Goldman S, Williams DA: Effects of recombinant human interleukin-11 on haematopoietic reconstitution in transplant mice: acceleration of recovery of peripheral blood neutrophils and platelets. Blood 1993; 81:27-34.
31. Yin T, Schendel P, Yu-Chung Y: Enhancement of in vivo and in vitro antigen specific antibody responses by interleukin-11. J Exp Med 1992; 175:211-216.
32. Mehler MF, Rozental R, Dougherty M, Spray DC, Kessler JA: Cytokine regulation of neuronal differentiation of hyppocampal progenitor cells. Nature 1993; 352:62-65.
33. Gordon MS, McCaskill-Stevens WJ, Battiato LA, et al.: A phase I trial of recombinant human interleukin-11 (Neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. Blood 1996; 87:3615-3624.
34. Ali-Nazir A, Davenport V, Reaman G, et al.: Preliminary results of a phase i/ii study of rhlL-11 following if osfamide carcoplatin and etoposide (ICE) chemotherapy in pediatric patients with solid tumours or lymphoma: enhancement of hematological reconstitution. Blood 1995; 86(1):686a.
35. Tepler I, Elias L, Smith JW, et al.: A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 1996; 87:3607-3614.
36. Kurzrock R, Estrov Z, Wetzler M, Guttermann JU, Talpaz M: LIF: not just a leukemia inhibitory factor. Endocrine Rev 1991; 12:208-217.
37. Sutherland GR, Baker E, Fernandez KE, et al.: The gene for human leukemia inhibitory factor (LIF) maps to 22q12. Leukemia 1989; 3:9-12.
38. Hilton DJ, Nicola NA, Metcalf D: Purification of a murine inhibitory factor from Krebs ascites cells. Analyt Biochem 1988; 173:359-367.
39. Godard A, Heymann D, Raher S, et al.: High and low affinity receptors for human interleukin for DA cells/leukemia inhibitory factor on human cells. Molecular characterization and cellular distribution. J Biol Chem 1992; 267:3214-3222.
40. Metcalf D, Hilton D, Nicola NA: Leukemia inhibitory factor can potentiate murine megakaryocyte production in vitro. Blood 1991; 77:2150-2153.
41. Ulich TR, Delcastillo J, Shin SS, et al.: Hematologic effects of stem cell factor (SCF) and leukemia inhibitory factor (LIF) in vivo-LIF induced thrombocytosis in SCF-primed mice. Eur J Haematol 1995; 54:217-225.
42. Baumann H, Wong GG: Hepatocyte stimulating factor III share structural and functional identity with leukemia inhibitory factor. J Immunol 1989; 143:1163-1167.
43. Shen MM, Leder P: Leukemia inhibitory factor is expressed by the preimplantation uterus and selectively blocks primitive ectoderm formation in vitro. Proc Nat Acad Sci 1992; 89:8240-8244.
44. Zarling JM, Shoyab M, Marquardt H, Hanson MB, Lioubin MN, Todaro DJ: Oncostatin M - a growth regulator produced by differentiated histiocytic lymphoma cells. Proc Nat Acad of Sci 1986; 83:9739-9743.
45. Rose TM, Bruce AG: Oncostatin M is a member of the cytokine family that includes leukemia inhibitory factor, granulocyte colony stimulating factor and interleukin-6. Proc Nat Acad of Sci 1991; 88:8641-8645.
46. Davis S, Aldrich TH, Stahl N, et al.: LIFR beta, and gp 130 as heterodimerizing signal transducers of the tripartite CNTF receptor. Science 1993; 260:1805-1808.
47. Miles SA, Martinez-Maza O, Rezai A, et al.: Oncostatin M as a potent mitogen for AIDS-Kaposi's sarcoma derived cells. Science 1992; 255:1432-1434.
48. Nair BC, DeVico AL, Nakamura S, et al.: Identification of a major growth factor for AIDS-Kaposi's sarcoma cells as oncostatin M. Science 1992; 255:1430-1432.
49. Grove RI, Mazzucco CE, Radka SF, Shoyab M, Kiener PA: Oncostatin M upregulates low density lipoprotein receptors in HepG2 cells by a novel mechanism. J Biol Chem 1991; 266:18194-18199.
50. Richards CD, Brown TJ, Shoyab M, Baumann H, Gauldie J: Recombinant Oncostatin M stimulates the production of acute phase proteins in HepG2 cells and rat primary hepatocytes in vitro. J Immunol 1992; 148:1731-1736.
51. Brown TJ, Rowe JM, Liu J, Shoyab M: Regulation of IL-6 expression by Oncostatin M. J Immunol 1991; 147:2175-2180.
52. Brown TJ, Liu J, Brashern-Stein C, Shoyab M: Regulation of granulocyte colony stimulating factor and granulocyte macrophage colony stimulating factor expression by Oncostin M. Blood 1993; 82:33-37.
53. Wallace PM, MacMaster JF, Rillema JR, Peng J, Burstein SA, Shoyab M: Thrombocytopoietic properties of oncostatin M. Blood 1995; 86:1310-1315.